Prematurity prevention: the role of progesterone


Autoria(s): FONSECA, Eduardo B. da; BITTAR, Roberto E.; DAMIAO, Rievani; ZUGAIB, Marcelo
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Purpose of review This review summarizes the evidence of the effectiveness of progesterone on the rate of preterm birth and evaluates the most recent studies. Recent findings The incidence of preterm delivery is about 7-11% of all pregnant women and preterm birth is one of the most important causes of neonatal morbidity and mortality. Interventions to reduce such complications have been attempted for several years. Most efforts so far have been tertiary interventions, such as treatment with antenatal corticosteroids, tocolytic agents, and antibiotics. Some of these measures have reduced perinatal morbidity and mortality, but the incidence of preterm birth is increasing. Recently, researches have suggested prophylactic progesterone could reduce the preterm birth rate in a select group presenting previous preterm birth and a short cervical length by transvaginal scan at mid-trimester pregnancy. Summary This review intends to define the current indication for administration of progesterone for pregnant women. On the basis of current knowledge, progesterone should be offered to women with a documented history of a previous spontaneous birth at less than 37 weeks and for those found to have a short cervical length of 15 mm or less. Studies are needed to evaluate progesterone efficacy on other risk factors.

Identificador

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, v.21, n.2, p.142-147, 2009

1040-872X

http://producao.usp.br/handle/BDPI/22341

10.1097/GCO.0b013e3283294770

http://dx.doi.org/10.1097/GCO.0b013e3283294770

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

Relação

Current Opinion in Obstetrics & Gynecology

Direitos

restrictedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #preterm birth #progesterone #recommendation #RECURRENT PRETERM DELIVERY #PLACEBO-CONTROLLED TRIAL #17-ALPHA-HYDROXYPROGESTERONE CAPROATE #DOUBLE-BLIND #PROGESTATIONAL AGENTS #CERVICAL LENGTH #MOUSE MODEL #BIRTH #PREGNANCY #WOMEN #Obstetrics & Gynecology
Tipo

article

original article

publishedVersion